|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang S, Sun T, Sun H, Li X, Li J, Zheng X,
Mallampati S, Sun H, Zhou X, Zhou C, et al: Survival improvement in
patients with non-small cell lung cancer between 1983 and 2012:
Analysis of the surveillance, epidemiology, and end results
database. Tumour Biol. 39:10104283176916772017.PubMed/NCBI
|
|
4
|
Rajabi M and Mousa SA: The role of
angiogenesis in cancer treatment. Biomedicines. 5:342017.
View Article : Google Scholar
|
|
5
|
Mahzouni P, Mohammadizadeh F, Mougouei K,
Moghaddam NA, Chehrei A and Mesbah A: Determining the relationship
between ‘microvessel density’ and different grades of astrocytoma
based on immunohistochemistry for ‘factor VIII-related antigen’
(von Willebrand factor) expression in tumor microvessels. Indian J
Pathol Microbiol. 53:605–610. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mineo TC, Ambrogi V, Baldi A, Rabitti C,
Bollero P, Vincenzi B and Tonini G: Prognostic impact of VEGF,
CD31, CD34, and CD105 expression and tumour vessel invasion after
radical surgery for IB-IIA non-small cell lung cancer. J Clin
Pathol. 57:591–597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abhinand CS, Raju R, Soumya SJ, Arya PS
and Sudhakaran PR: VEGF-A/VEGFR2 signaling network in endothelial
cells relevant to angiogenesis. J Cell Commun Signal. 10:347–354.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramjiawan RR, Griffioen AW and Duda DG:
Anti-angiogenesis for cancer revisited: Is there a role for
combinations with immunotherapy? Angiogenesis. 20:185–204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nielsen J, Christiansen J, Lykke-Andersen
J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like
growth factor II mRNA-binding proteins represses translation in
late development. Mol Cell Biol. 19:1262–1270. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Er LM, Li Y, Wu ML, Zhao Q, Tan BB, Wang
XL and Wang SJ: Expression of IMP3 as a marker for predicting poor
outcome in gastroenteropancreatic neuroendocrine neoplasms. Oncol
Lett. 13:2391–2396. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ikenberg K, Fritzsche FR, Zuerrer-Haerdi
U, Hofmann I, Hermanns T, Seifert H, Müntener M, Provenzano M,
Sulser T, Behnke S, et al: Insulin-like growth factor II mRNA
binding protein 3 (IMP3) is overexpressed in prostate cancer and
correlates with higher Gleason scores. BMC Cancer. 10:3412010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang K, Zhou M, Chen H, Wu G, Chen K and
Yang H: Expression of IMP3 and IGF2 in giant cell tumor of spine is
associated with tumor recurrence and angiogenesis. Clin Transl
Oncol. 17:570–575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen P, Wang SJ, Wang HB, Ren P, Wang XQ,
Liu WG, Gu WL, Li DQ, Zhang TG and Zhou CJ: The distribution of
IGF2 and IMP3 in osteosarcoma and its relationship with
angiogenesis. J Mol Histol. 43:63–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kay FU, Kandathil A, Batra K, Saboo SS,
Abbara S and Rajiah P: Revisions to the Tumor, Node, Metastasis
staging of lung cancer (8th edition): Rationale, radiologic
findings and clinical implications. World J Radiol. 9:269–279.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abdel-Rahman O: Validation of the
prognostic value of new sub-stages within the AJCC 8th edition of
non-small cell lung cancer. Clin Transl Oncol. 19:1414–1420. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schaeffer DF, Owen DR, Lim HJ, Buczkowski
AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS and Owen DA:
Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3)
overexpression in pancreatic ductal adenocarcinoma correlates with
poor survival. BMC Cancer. 10:592010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis-correlation in invasive breast
carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu M, Tian Y, Yue WM, Li L, Li SH, Qi L,
Hu WS, Gao C, Si LB and Tian H: GOLPH3, a good prognostic indicator
in early-stage NSCLC related to tumor angiogenesis. Asian Pac J
Cancer Prev. 15:5793–5798. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bacic I, Karlo R, Zadro AS, Zadro Z,
Skitarelic N and Antabak A: Tumor angiogenesis as an important
prognostic factor in advanced non-small cell lung cancer (Stage
IIIA). Oncol Lett. 15:2335–2339. 2018.PubMed/NCBI
|
|
20
|
Marrogi AJ, Travis WD, Welsh JA, Khan MA,
Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE,
et al: Nitric oxide synthase, cyclooxygenase 2, and vascular
endothelial growth factor in the angiogenesis of non-small cell
lung carcinoma. Clin Cancer Res. 6:4739–4744. 2000.PubMed/NCBI
|
|
21
|
Wehland M, Bauer J, Infanger M and Grimm
D: Target-based anti-angiogenic therapy in breast cancer. Curr
Pharm Des. 18:4244–4257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Yao X, Ge J, Hu F and Zhao Y: Can
vascular endothelial growth factor and microvessel density be used
as prognostic biomarkers for colorectal cancer? A systematic review
and meta-analysis. ScientificWorldJournal.
2014:1027362014.PubMed/NCBI
|
|
23
|
Chang Y, Niu W, Lian PL, Wang XQ, Meng ZX,
Liu Y and Zhao R: Endocan-expressing microvessel density as a
prognostic factor for survival in human gastric cancer. World J
Gastroenterol. 22:5422–5429. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mahecha AM and Wang H: The influence of
vascular endothelial growth factor-A and matrix metalloproteinase-2
and −9 in angiogenesis, metastasis and prognosis of endometrial
cancer. Onco Targets Ther. 10:4617–4624. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chand R, Chandra H, Chandra S and Verma
SK: Role of microvessel density and vascular endothelial growth
factor in angiogenesis of hematological malignancies. Bone Marrow
Res. 2016:50434832016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thielemann A, Kopczynski Z, Filas V,
Breborowicz J, Grodecka-Gazdecka S and Baszczuk A: The
determination of VEGF and MVD, among patients with primary breast
cancer. Pathol Oncol Res. 14:137–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fontanini G, Vignati S, Boldrini L, Chinè
S, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G:
Vascular endothelial growth factor is associated with
neovascularization and influences progression of non-small cell
lung carcinoma. Clin Cancer Res. 3:861–865. 1997.PubMed/NCBI
|
|
28
|
Iwasaki A, Kuwahara M, Yoshinaga Y and
Shirakusa T: Basic fibroblast growth factor (bFGF) and vascular
endothelial growth factor (VEGF) levels, as prognostic indicators
in NSCLC. Eur J Cardiothorac Surg. 25:443–448. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bonnesen B, Pappot H, Holmstav J and Skov
BG: Vascular endothelial growth factor A and vascular endothelial
growth factor receptor 2 expression in non-small cell lung cancer
patients: Relation to prognosis. Lung Cancer. 66:314–318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yano T, Tanikawa S, Fujie T, Masutani M
and Horie T: Vascular endothelial growth factor expression and
neovascularisation in non-small cell lung cancer. Eur J Cancer.
36:601–609. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Su P, Hu J, Zhang H, Li W, Jia M, Zhang X,
Wu X, Cheng H, Xiang L and Zhou G: IMP3 expression is associated
with epithelial-mesenchymal transition in breast cancer. Int J Clin
Exp Pathol. 7:3008–3017. 2014.PubMed/NCBI
|
|
32
|
Suvasini R, Shruti B, Thota B, Shinde SV,
Friedmann-Morvinski D, Nawaz Z, Prasanna KV, Thennarasu K, Hegde
AS, Arivazhagan A, et al: Insulin growth factor-2 binding protein 3
(IGF2BP3) is a glioblastoma-specific marker that activates
phosphatidylinositol 3-kinase/mitogen-activated protein kinase
(PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem.
286:25882–25890. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liao B, Hu Y and Brewer G: RNA-binding
protein insulin-like growth factor mRNA-binding protein 3 (IMP-3)
promotes cell survival via insulin-like growth factor II signaling
after ionizing radiation. J Biol Chem. 286:31145–31152. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liao B, Hu Y, Herrick DJ and Brewer G: The
RNA-binding protein IMP-3 is a translational activator of
insulin-like growth factor II leader-3 mRNA during proliferation of
human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Samanta S, Sharma VM, Khan A and Mercurio
AM: Regulation of IMP3 by EGFR signaling and repression by ERb:
Implications for triple-negative breast cancer. Oncogene.
31:4689–4697. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA,
Rock KL and Kwon ED: Oncofetal protein IMP3: A novel molecular
marker that predicts metastasis of papillary and chromophobe renal
cell carcinomas. Cancer. 112:2676–2682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li C, Rock KL, Woda BA, Jiang Z, Fraire AE
and Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ
of the uterine cervix: An immunohistochemical study in comparison
with p16 (INK4a) expression. Mod Pathol. 20:242–247. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kobel M, Xu H, Bourne PA, Spaulding BO,
Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, et
al: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis
in ovarian carcinoma of clear cell subtype. Mod Pathol. 22:469–475.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao W, Lu D, Liu L, Cai J, Zhou Y, Yang
Y, Zhang Y and Zhang J: Insulin-like growth factor 2 mRNA binding
protein 3 (IGF2BP3) promotes lung tumorigenesis via attenuating p53
stability. Oncotarget. 8:93672–93687. 2017.PubMed/NCBI
|
|
40
|
Findeis-Hosey JJ and Xu H: Insulin-like
growth factor II-messenger RNA-binding protein-3 and lung cancer.
Biotech Histochem. 87:24–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Beljan Perak R, Durdov MG, Capkun V,
Ivcevic V, Pavlovic A, Soljic V and Peric M: IMP3 can predict
aggressive behaviour of lung adenocarcinoma. Diagn Pathol.
7:1652012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen L, Xie Y, Li X, Gu L, Gao Y, Tang L,
Chen J and Zhang X: Prognostic value of high IMP3 expression in
solid tumors: A meta-analysis. Onco Targets Ther. 10:2849–2863.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Findeis-Hosey JJ, Yang Q, Spaulding BO,
Wang HL and Xu H: IMP3 expression is correlated with histologic
grade of lung adenocarcinoma. Hum Pathol. 41:477–484. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park JY, Choe M, Kang Y and Lee SS: IMP3,
a promising prognostic marker in clear cell renal cell carcinoma.
Korean J Pathol. 48:108–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gharib TG, Chen G, Huang CC, Misek DE,
Iannettoni MD, Hanash SM, Orringer MB and Beer DG: Genomic and
proteomic analyses of vascular endothelial growth factor and
insulin-like growth factor-binding protein 3 in lung
adenocarcinomas. Clin Lung Cancer. 5:307–312. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Niu G and Chen X: Vascular endothelial
growth factor as an anti-angiogenic target for cancer therapy. Curr
Drug Targets. 11:1000–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kwon YW, Kwon KS, Moon HE, Park JA, Choi
KS, Kim YS, Jang HS, Oh CK, Lee YM, Kwon YG, et al: Insulin-like
growth factor-II regulates the expression of vascular endothelial
growth factor by the human keratinocyte cell line HaCaT. J Invest
Dermatol. 123:152–158. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mathur RS and Mathur SP: In vitro
downregulation of growth factors by insulin-like growth factor
binding protein-3 in cervical cancer. Gynecol Oncol. 91:410–415.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Han JY, Oh SH, Morgillo F, Myers JN, Kim
E, Hong WK and Lee HY: Hypoxia-inducible factor 1alpha and
antiangiogenic activity of farnesyltransferase inhibitor SCH66336
in human aerodigestive tract cancer. J Natl Cancer Inst.
97:1272–1286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Oh SH, Kim WY, Kim JH, Younes MN,
El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK and Lee
HY: Identification of insulin-like growth factor binding protein-3
as a farnesyl transferase inhibitor SCH66336-induced negative
regulator of angiogenesis in head and neck squamous cell carcinoma.
Clin Cancer Res. 12:653–661. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee HY, Chun KH, Liu B, Wiehle SA,
Cristiano RJ, Hong WK, Cohen P and Kurie JM: Insulin-like growth
factor binding protein-3 inhibits the growth of non-small cell lung
cancer. Cancer Res. 62:3530–3537. 2002.PubMed/NCBI
|
